Scaling new heights in the fight against heart disease
We are focused on advancing our clinical-stage lead gene therapy programs, TN-201 for MYBPC3-associated HCM and TN-401 for PKP2-associated ARVC.
We are a biotechnology company committed to a bold mission: to discover, design, develop and deliver potentially curative therapies that address the underlying drivers of heart disease.
Founded by leading cardiovascular scientists, our team has the tenacity to pursue our ultimate peak – changing the treatment paradigm for heart disease, and in doing so improving and extending the lives of millions of individuals and families fighting these debilitating conditions.
LATEST NEWS
Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction Count TN-401 Gene Therapy was Well Tolerated at 3E13 vg/kg and 6E13 vg/kg Doses Post-dose Biopsies Provide Evidence of TN-401 Activity in Heart Muscle Cells PRIME Designation Granted by European
Read MoreTenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
One-Year Cohort 1 Data and Initial Cohort 2 Data from RIDGE™-1 Phase 1b/2 Trial of TN-401 for PKP2-Associated ARVC to be Presented at ASGCT 2026 New Data from Both Cohorts of the MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM Expected in the Second Quarter 2026
Read MoreTenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026
Readout to Include One-Year Cohort 1 Results and Early Cohort 2 Data; Webcast Conference Call Planned to Review RIDGE-1 Data at ASGCT Additional Presentations at ASGCT Showcase Tenaya’s Work with Patients to Advance Gene Therapy and Early-Stage Pipeline Innovations in Cardiac Gene Editing SOUTH
Read More
PATIENTS FIRST
Here at Tenaya, we strive to make the needs of patients our top priority in all we do. As we develop new medicines aimed at targeting the genetic underpinnings of cardiomyopathies, we’ve sought input from patients and their families all along the way to better understand how genetic conditions like hypertrophic cardiomyopathy and arrhythmogenic right ventricular impact their lives daily and over time. We’ve also created resources to help patients, their families and their physicians better understand how gene therapies work and what to expect from our clinical trials.